Generate Biomedicines, Inc. (GENB)
Healthcare
Biotechnology
14.00 $
-0.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Generate Biomedicines, Inc. (GENB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -80 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q1 25 | Q1 26 |
|---|---|---|
| -53 | -80 | |
| 3.4 | 3.3 | |
| 4.7 | 6.4 | |
| -17 | -31 | |
| 0.8 | 3.8 | |
| – | -252 | |
| -2.6 | -1.1 | |
| 21 | 371 | |
| 43 | 161 | |
| -54 | -84 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.